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Abstract
Malnutrition in cystic ﬁbrosis (CF) is associated with increased mortality and can lead to fat-free (FFM) and fat mass (FM) loss. Dual-energy X-ray
absorptiometry (DXA) is used and validated to measure FFM and FM. DXA's high cost has led to the utilization of less costly techniques such as
bioelectrical impedance analysis (BIA). The aim of this study was to determine the agreement of FFM, FM and %FMmeasurements taken with DXA
and BIA in adults with CF. We measured FFM, FM and %FM in 34 adults with CF with a leg-to-leg BIA and an iDXA and determined agreement
using Bland–Altman analysis. While DXA and BIA measurements were well correlated (r N 0.8), mean biases between both methods were between 8
and 11%. BIA underestimated FM and %FM and overestimated FFM. In a clinical research setting where these measurements are used to phenotype
patients, BIA cannot replace DXA.
© 2014 Elsevier B.V. All rights reserved. on behalf of European Cystic Fibrosis Society.Keywords: Body composition; Bioelectrical impedance analysis; Dual-energy X-ray absorptiometry; Bland–Altman analysis1. Introduction
Cystic fibrosis (CF) is the most common autosomal genetic
disease among Caucasians [1] and is associated with exocrine
pancreatic insufficiency [2] and malnutrition [3]. Malnutrition
can lead to fat-free (FFM; bones, muscles and organ mass) and
fat mass (FM) loss [4]. Studies have suggested that loss of FFM
is associated with lung disease and disease severity [3,5,6], and
that body mass index (BMI) is not sensitive enough to detect
its depletion [5,6]. It is important to accurately detect malnutrition
by measuring FFM and FM losses as they are linked with
decreased lung functions and increased mortality in CF [3].⁎ Corresponding author at: IRCM, 110, avenue des Pins Ouest, Montréal, Québec
H2W 1R7, Canada. Tel.: +1 514 987 5762; fax: +1 514 987 5670.
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http://dx.doi.org/10.1016/j.jcf.2014.01.006ehalf oDual-energy X-ray absorptiometry (DXA) was first developed to
evaluate bone mass but is also widely used and validated to
measure FFM and FM [7]. The DXA uses X-rays with two
different energy levels. Then, the energy of the attenuated
rays is used in equations and the DXA can determine if the
matter scanned is either fat-free mass, fat mass or bone [8].
DXA's high cost has led to the utilization of less costly
techniques such as bioelectric impedance analysis (BIA)
for body composition analysis. Leg-to-leg BIA uses an electric
current that runs from one foot to the other and uses the
resistance of mass to determine if it is either FM or FFM [9].
Three studies in patients with CF have compared these two
techniques and reported discordant results [10,12]. While Pichard
et al. reported good agreement of FFM between BIA and DXA
[10], King et al. showed that BIA incorrectly estimated FFM
in adults with CF [11]. Furthermore, Beaumesnil et al. foundf European Cystic Fibrosis Society.
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children and adults with CF [12]. None of these studies evaluated
the accuracy of BIA to measure FFM, FM and percentage FM
(%FM) in a group of adults with CF. Therefore, the aim of this
study was to determine the agreement between measurements
of FFM, FMand%FM takenwith BIA andDXA in adults with CF.
2. Material and methods
This cross sectional study included 34 adults with CF (15
men and 19 women) and is a sub-analysis of a larger project
studying CF-related diabetes. All CF subjects were recruited
from the Centre Hospitalier de l'Université de Montréal
(CHUM) and tested at the Institut de Recherches Cliniques
de Montréal (IRCM). Participants were excluded if they were
pregnant or having a pulmonary exacerbation diagnosed by
a CF pulmonologist of the CHUM and defined by a change
in sputum production (volume, colour, consistency), new or
increased haemoptysis, increased cough, increased dyspnoea,
fatigue or lethargy, fever N38 °C, anorexia, sinus pain, a N10%
decrease in FEV1 compared to previously recorded values,
intravenous antibiotic treatment and change in chest sounds [13].
The protocol was approved by the Research Ethics Committees
of the CHUM and IRCM. Study participants did not fast prior
to the tests but did not ingest caffeine or do any type of physical
exercise 8 h before. Tests were done while participants were
wearing light clothing and no metal objects.
After measuring weight and height, all subjects performed
a barefoot leg-to-leg BIA using a Tanita Body Composition
Analyzer TBF-310 (Tanita Corporation of America, Arlington
Heights, IL, USA) and a DXA using a Lunar iDXA (GE
HealthCare, Mississauga, ON, Canada) to estimate FFM, FM and
%FM. For the DXA, all subjects were lying supine on a flat couch
for 15–30 min. The DXA was calibrated with a phantom every
morning before scans.
2.1. Statistics
Data are expressed in either mean ± standard deviation (SD)
(for age, BMI) or median ± interquartile range (IQR) (for FFM,
FM, %FM) depending on whether they are normally distributed.
Statistical analysis was done with R (R 2.13.0). We comparedTable 1
Characteristics of subjects with cystic fibrosis (CF).
Total (n = 34)
Age (years) 30 ± 9 [20–48]
BMI (kg/m2) 22.0 ± 2.56 [17.8–27.9]
FFM (kg) a 43.4 ± 10.3 [29.8–66.4]
FM (kg) a 14.2 ± 8.27 [4.82–27.6]
%FMa 23.5 ± 12.38 [8.8–38.8]
FFM (kg) b 46.6 ± 8.85 [37.8–61.2]
FM (kg) b 12.9 ± 8.65 [3.8–25.4]
%FMb 21.2 ± 13.3 [7.6–36.3]
BMI: body mass index, FM: fat mass, FFM: fat free mass.
a Measured with dual-energy X-ray absorptiometry.
b Measured with bioimpedance analysis.
# p ≤ 0.0083 vs men.measures of FFM, FM and %FM taken with DXA and BIA
between men and women using Wilcoxon signed-rank tests.
We corrected for multiple comparisons and considered that a
p ≤ 0.0083 was significant (p = 0.05/6 comparisons = 0.0083).
We also associated FFM, FM and %FM measured by DXA and
BIA using Spearman correlations. Then, Bland–Altman (BA)
analysis was used to evaluate agreement of bothmethods [14]. Bias
was defined as the percentage difference between both methods
((BIA − DXA) / DXA ∗ 100) for measures of FFM, FM and
%FM and limits of agreement were ±2 standard deviations (SDs)
of the bias.
3. Results
Characteristics of 34 adults with CF included in the study
are shown in Table 1. Study participants were 30 ± 9 years old
and had a wide range of BMIs varying from 17.8 to 27.9 kg/m2
with an average of 22.0 ± 2.56 kg/m2. Average FFM, FM and
%FM are also shown in Table 1 and they were statistically
different between men and women (p ≤ 0.0083).
Fig. 1 illustrates the associations between measures of FFM
(A), FM (B) and %FM (C) obtained with DXA (D) and BIA
(B). The associations between FFM, FM and%FMmeasurements
were strongwith correlation coefficients of 0.915, 0.914 and 0.833
respectively.
The mean bias for FFM was −8.04%, 10.2% for FM and
9.79% for %FM. BA analysis plots showing the distribution
of the biases for FFM (A), FM (B) and %FM (C) are
presented in Fig. 2. The biases of FFM are heterogeneously
distributed. There is a trend for BIA overestimating FFM for
people with b40 kg of FFM and underestimating for the
others. The distributions of FM and %FM biases are also
heterogeneous. BIA seems to underestimate FM and %FM in
individuals with b20 kg (~15%) of FM. Results of mean biases
for FM, %FM and FFM were similar between men and women
(results not shown).
4. Discussion
Although measures taken with both techniques were highly
correlated, mean biases between both methods were between
8 and 11% for all three measurements using BA analysis.Men (n = 15) Women (n = 19)
29.1 ± 8.72 [20–45] 30.8 ± 8.97 [20–54]
22.0 ± 2.98 [18.1–27.9] 22.0 ± 2.25 [17.8–26.1]
47.7 ± 7.51 [40.7–66.4] 39.2 ± 6.56 [29.8–50.7] #
8.91 ± 6.85 [4.82–27.6] 16.4 ± 6.47 [9.00–25.3] #
14.8 ± 6.45 [8.80–31.7] 28.7 ± 8.90 [17.1–38.8] #
50.4 ± 8.00 [42.8–69.0] 41.6 ± 4.10 [37.8–47.8] #
8.20 ± 8.70 [3.8–25.4] 14.6 ± 8.90 [7.60–25.2] #
13.9 ± 10.0 [7.6–29.4] 26.7 ± 9.00 [16.3–36.3] #
r=0.915
r=0.914
r=0.833
A)
B)
C)
Fig. 1. Spearman correlations of body composition measurements ((A)
fat-free mass (FFM), (B) fat mass (FM), (C) percentage fat mass (%FM))
taken by bioelectric impedance analysis (B) and dual-energy X-ray absorpti-
ometry (D) in adults with cystic fibrosis.
+ 2 SD
-2 SD
+ 2 SD
-2 SD
Mean Bias =10.2% 
Mean Bias =9.79% 
+ 2 SD
-2 SD
Mean Bias =-8.04%
A)
B)
C) 
Fig. 2. Bland–Altman analysis plots of the percentage difference between
bioelectric impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA)
in measuring (A) fat-free mass (FFM), (B) fat mass (FM), and (C) percentage fat
mass (%FM)) in adults with cystic fibrosis.
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Assuming that BIA error is constant over time, these differences
might not have a significant impact if clinicians are evaluating
the differences of body composition measures from one visit
to the other. However, in a research setting, where precise FFM,
FM and %FM values are used to phenotype patients, BIA may
not replace DXA.
Our study is the first to compare FFM, FM and %FM
measurements taken with DXA and BIA in adults with CF.
The aim of this study was to determine the agreement of
body composition measurements taken with two widely used
non-invasive methods. If both techniques were comparable,we could replace the DXA with minimal X-ray exposure in a
population already highly exposed [15] with the leg-to-leg
BIA. However, in line with results reported by King et al.
[11], the biases found are relevant in a research setting making
it inappropriate to replace DXA with the BIA. These biases
could be explained, by altered sodium content in the sweat
of people with CF [9]. To overcome this problem, the use
of specific equations has been suggested [9], however most
commercial devices do not allow using specific formulas for a
sub-group of patients. As bias could be affected by the amount
of FFM and FM, future studies should include patients with
low, normal and high FFM and FM.
588 S. Ziai et al. / Journal of Cystic Fibrosis 13 (2014) 585–588In conclusion, we suggest that DXA cannot be replaced
by BIA to measure FFM, FM and %FM in adults with CF in a
research setting.Conﬂicts of interest
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